Profile
Sector:
HealthcareCountry:
IsraelIPO:
01 September 2020Website:
http://www.painreform.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 22 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
PRFX Latest News
TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 989,300 ordinary shares of the Company originally issued in December 2023 and April 2024, having an exercise price of $4.80 per share, at a reduced exercise price of $1.60 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (File No. 333-276485) and Form F-1 (File No. 333-277594). The offering is expected to close on or about September 11, 2024, subject to satisfaction of customary closing conditions.
TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced encouraging early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, the Company's proprietary post-surgical pain formulation.
TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110's promising safety profile, with maximum blood levels (Cmax) recorded at approximately 10% of the FDA-established safety threshold.
New process expected to significantly bolster future commercialization efforts New process expected to significantly bolster future commercialization efforts
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.
PainReform (NASDAQ: PRFX ) stock is rallying on Thursday after the pharmaceutical company regained compliance with Nasdaq listing requirements. According to the company's press release, it was sent notice of it regaining compliance on July 18.
In the world of biotech stocks, one company that's generating big buzz today is PainReform (NASDAQ: PRFX ). The Israeli clinical-stage pharmaceutical company has seen its stock price absolutely skyrocket.
PainReform (NASDAQ: PRFX ) stock is falling on Wednesday after the company announced a concurrent registered direct offering and private placement. The registered direct offering has PainReform agreeing to sell 301,230 shares of PRFX stock at a price of $9 per share.
What type of business is PainReform?
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
What sector is PainReform in?
PainReform is in the Healthcare sector
What industry is PainReform in?
PainReform is in the Drug Manufacturers - Specialty & Generic industry
What country is PainReform from?
PainReform is headquartered in Israel
When did PainReform go public?
PainReform initial public offering (IPO) was on 01 September 2020
What is PainReform website?
https://www.painreform.com
Is PainReform in the S&P 500?
No, PainReform is not included in the S&P 500 index
Is PainReform in the NASDAQ 100?
No, PainReform is not included in the NASDAQ 100 index
Is PainReform in the Dow Jones?
No, PainReform is not included in the Dow Jones index
When was PainReform the previous earnings report?
No data
When does PainReform earnings report?
Next earnings report date is not announced yet